Abstract 3854: Newly designed nanobioconjugate for direct targeting and systemic treatment of HER2-positive breast cancer

@article{Inoue2010Abstract3N,
  title={Abstract 3854: Newly designed nanobioconjugate for direct targeting and systemic treatment of HER2-positive breast cancer},
  author={Satoshi Inoue and Hui Ding and Bindu Konda and Jos{\'e} Antonio Portilla-Arias and Rameshwar Patil and Andreas Espinoza and Sergiy Rudenkyy and Manuel L. Penichet and Marisa Riley and Marcus Gates and Eggehard Holler and Keith L. Black and Julia Y. Ljubimova},
  journal={Cancer Research},
  year={2010},
  volume={70},
  pages={3854-3854}
}
Objective: We have developed an efficient nanobipolymer drug delivery system Polycefin based on natural-derived biodegradable, non-toxic and non-immunogenic polymalic acid (PMLA) platform. We have shown that Polycefin was able to block brain tumor growth and angiogenesis. Our goal is to engineer the new Polycefin variant for systemic (I.V.) treatment of HER2-positive breast tumors in order to enhance the efficacy of trastuzumab/Herceptin®. Materials and Methods: For in vitro and in vivo…